Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
13.39
+0.59 (4.61%)
Dec 3, 2025, 3:29 PM EST - Market open
Alto Neuroscience Employees
Alto Neuroscience had 76 employees as of December 31, 2024.
Employees
76
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$819,171
Market Cap
415.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANRO News
- 5 days ago - Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 - Seeking Alpha
- 21 days ago - Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 weeks ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Alto Neuroscience Announces $50 Million Private Placement Financing - Business Wire
- 6 weeks ago - Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Business Wire
- 2 months ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 2 months ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 2 months ago - Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - Business Wire